FirstWord’s Biosimilar Index is a comprehensive drug intelligence service that provides a robust, dynamically updated and highly-detailed insight into the status of leading biosimilar and NCB assets in development worldwide. Exhaustively referenced and sourced, it is one of the most comprehensive analyses of its type providing both on-going tracking of development and interpretation of the commercial and clinical significance.
Biosimilar Index now includes details of 620 biosimilar and NCB programmes and is segmented by developing company, reference molecule, market status and therapeutic class, making it one of the most detailed biosimilar market tracking tools available today. Biosimilar Index provides a collection of key journal articles, news stories, key regulatory developments, licensing availability and partnering information for all key programmes. All information is sorted in an easy-to-search tab of the datafile with links to source information.
Biosimilar R&D activity is at an all-time high and, at this critical stage in the market’s evolution, it is vital to fully understand the biosimilar and non-comparable biologic (NCB) pipeline and be able to draw reliable conclusions about what is, and is not, significant. That is where the Biosimilar Index comes in.
Now Available
Podcast: Interview with Dr Paul Calvo, IP and Legal Expert
Webinar [On-Demand]: What’s Next for Biosimilars? History, Current Status and Future Expectations
Two Comprehensive Services in One Subscription |
|
Biosimilar Index: Pipeline Datafile Updated every two weeks, this Datafile provides up-to-date insight of biosimilar and NCB drugs in development from over 189 companies worldwide. The Datafile can be downloaded (as often as you need) in MS Excel™ format. The latest version of the Biosimilar Index datafile includes details of 593 biosimilar and NCB programmes. It continues to be segmented by developing company (n=189 companies), reference molecule (n=54 molecules), market status (n=17 markets) and therapeutic class (n=16 classes), making it one of the most detailed biosimilar market tracking tools available today. The datafile also includes (1) a list of approved biosimilars from several of the key developed and emerging markets; (2) a summary of all key product updates since the service began back in March 2014; (3) a collection of key biosimilar-focused journal articles, news stories and key regulatory developments and; (4) licensing availability and partnering information for all key programmes. |
Biosimilar Index Landscape Review Published monthly and delivered in MS PowerPoint™, the Landscape Review is packed with slides of tables and charts on key reference medicinal product data, current and future market milestones, extensive product-by product reviews and relevant clinical trial activity. The Landscape Review is based on the updated research in the Biosimilar Index: Pipeline Datafile and enhanced by critical insights from in house and external biosimilar experts. The latest version includes market landscape summaries and detailed reviews of all key clinical trials across a wide number of molecules, including all key monoclonal antibodies (mAbs), fusion proteins, insulin, EPO-alfa, filgrastim, follicle stimulating hormone, interferon-alfa and interferon-beta. Also includes a review of the latest news and events in the biosimilars market and FirstView's proprietary Biosimilars Market Catalyst Calendar which aims to provide visibility of several key future milestones in the biosimilars market. |
With Biosimilar Index you can...
The Biosimilar Index is feature rich...
For multi-user pricing, please contact us at info@firstviewreports.com
The Biosimilars Index: Pipeline Datafile is checked regularly. When a significant event happens, the datafile is updated, thereby ensuring you’re up to date with current market dynamics. The datafile is provided as a dynamic MS Excel™ file with complete data and filter analysis tools included. Available 24/7 through a secure password protected site, there are no limits on how frequently you can download the XLS file. Having access to the datafile enables you to see the whole biosimilar and NCB landscape across multiple classes and geographies
Essential details covered in the datafile include:
Powerful data with intuitive analysis tools
With Biosimilars Index: Pipeline Datafile at hand, you can effortlessly compare and contrast biosimilars in development by country, originator company, stage of development, condition and therapeutic area. The data is provided in MS Excel™ and comes with filters and search built in. The data can easily be exported to your own analytics package or data visualisation platform.
What’s hot and what’s not? The biosimilars sector is constantly evolving. Important research progress, commercial deals and product launches are regularly announced. The Biosimilar Index: Landscape Review strips away market rumour and speculation to tell you exactly what has happened and why it is important. Published monthly, the Landscape Review is based on the daily-updated research in the Biosimilar Index: Pipeline Datafile, enhanced by critical insights and understanding from biosimilars experts.
Benefits and Features of the Biosimilar Index: Landscape Review
Duncan Emerton, Senior Director Syndicated Insights and Analytics
FirstWord’s Biosimilar Index is headed up by Dr Duncan Emerton, a recognised expert in the biosimilar field.
With over 15 years clinical research and commercial analysis experience gained with Pfizer and Datamonitor, Duncan brings a unique and informed perspective to the expanding market for biosimilars and the commercial, clinical and regulatory challenges it faces.
Duncan is a regular presenter and Chair at biosimilar-focused conferences and has contributed several acclaimed articles and book chapters on key issues including lifecycle management, profitability, commercialisation and strategy.
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved